Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of OsrhCT in Patients with Pleurisy
NCT06525272Phase 1Not yet recruiting
- Sponsor
- Wuhan Healthgen Biotechnology Corp.
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Recombinant Human Chymotrypsin in pleurisy (4 arms), sponsored by Wuhan Healthgen Biotechnology Corp. Primary endpoint: Adverse Events and Serious Adverse Events at 30 days. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
Recombinant Human Chymotrypsin
03
Conditions
pleurisy
Beyond the preview
Go deeper on NCT06525272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525272.